Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Forensic toxicology is the study of the pharmacodynamics, or what a substance does to the body, and pharmacokinetics, or what the body does to the substance. To accurately determine the effect a particular drug has on the human body, forensic toxicologists must be aware of various levels of drug tolerance that an individual can build up as well as the therapeutic index for various pharmaceuticals. Toxicologists are tasked with determining whether any toxin found in a body was the cause of or contributed to an incident, or whether it was at too low a level to have had an effect. While the determination of the specific toxin can be time-consuming due to the number of different substances that can cause injury or death, certain clues can narrow down the possibilities. For example, carbon monoxide poisoning would result in bright red blood while death from hydrogen sulfide poisoning would cause the brain to have a green hue. Toxicologists are also aware of the different metabolites that a specific drug could break down into inside the body. For example, a toxicologist can confirm that a person took heroin by the presence in a sample of 6-monoacetylmorphine, which only comes from the breakdown of heroin. The constant creation of new drugs, both legal and illicit, forces toxicologists to keep themselves apprised of new research and methods to test for these novel substances. The stream of new formulations means that a negative test result does not necessarily rule out drugs. To avoid detection, illicit drug manufacturers frequently change the chemicals' structure slightly.
988 (telephone number) Abnormal psychology Emotional resilience Ethnopsychopharmacology History of mental disorders Mental environment Mental health day Mental health during the COVID-19 pandemic Mental health first aid Mental health in education Mental health in the workplace Mental health of Asian Americans Self-help groups for mental health Social determinants of mental health Social stigma Suicide awareness Telemental health World Mental Health Day Well-being
Patients being treated for osteoporosis or non-malignant bone disease with oral bisphosphonates/quarterly or yearly infusions of intravenous bisphosphonates for >5 years Patients being treated for osteoporosis or non-malignant bone disease with bisphosphonates/denosumab for any length of time as well as being treated with systemic glucocorticoids Patients being treated with anti-resorptive/anti-angiogenic drugs/both as part of cancer management Previous MRONJ diagnosis "N.B. Patients who have taken bisphosphonate drugs at any time in the past and those who have taken denosumab in the last nine months are allocated to a risk group as if they are still taking the drug."
== Focus of Transfusion Practitioners == It is a specialist role focusing on patient safety through best practice and appropriate use of blood and blood products. Much of the work of TPS centres on aligning practices with local, national, or international standards and guidelines. There are many activities that comprise the TP role and some or all of these may be within TPs position (job) descriptions depending on the area they work, and the strategic direction of the organisation they work in. TP activities aim to increase awareness and knowledge to improve clinical decision making and enhance practice. Transfusion practice require a multidisciplinary approach and TPs are seen as the link between different health professionals and departments, such as clinical and laboratory colleagues, as well as patients. To comply with governance, regulations and mandatory standards many organisations have established Blood Management Committees or Hospital Transfusion Committees. A TPs responsibilities include risk management, surveillance of appropriate use, coordinating patient blood management strategies, blood waste minimisation and investigation and analysis of events. These committees ideally include multidisciplinary membership, and provide support, guidance, and endorsement of the TP activities. The TP plays an essential role in supporting the work of the committee. Transfusion Practitioners improve transfusion practice by promoting safe transfusion practice in a variety of ways. Activities of the TP may include:
Sources: en.wikipedia.org
=== Criticism of expert witnesses === Several medical experts have questioned the reliability of the prosecution's expert witness, Dewi Evans. Svilena Dimitrova, an NHS consultant neonatologist, and Roger Norwich, a medico-legal expert, submitted formal complaints to the General Medical Council regarding Evans's evidence. Dimitrova told The Guardian that she believed "the theories proposed in court were not plausible and the prosecution was full of medical inaccuracies", adding that while she could not assert Letby's innocence, she saw "no proof of guilt". Evans rejected suggestions of bias and noted that the defence could have called its own expert witnesses at trial but did not do so. Other prosecution experts broadly supported Evans' conclusions. The New Yorker reported that in an unrelated earlier case, a Court of Appeal judge had described one of Evans's expert reports as "worthless", containing opinions that were "tendentious and partisan" and outside his professional competence. Another paediatrician who testified as an expert for the prosecution has since resigned from her position as a consultant following multiple complaints about her practice. The prosecution's endocrinologist, Peter Hindmarsh, was under investigation by the General Medical Council (GMC) when he gave evidence during the trial. The investigation was prompted by "multiple and wide-ranging concerns" about his practice from both of the hospitals he was affiliated with. A medical tribunal placed restrictions on his ability to practise, arguing that he "may pose a real risk to members of the public".
Methods for the incorporation of click reaction partners into systems in and ex vivo contribute to the scope of possible bioconjugation reactions. The development of unnatural amino acid incorporation by ribosomes has allowed for the incorporation of click reaction partners as unnatural side groups on these unnatural amino acids. For example, azidohomoalanine (AHA) is a methionine analog with an azide side group. This azide side group allows cycloalkynes to react to proteins that incorporate this "AHA" unnatural amino acid. In another example, "CpK" is a lysine analog. CpK has a side group including a cyclopropane alpha to an amide bond that serves as a reaction partner to tetrazine in an inverse diels-alder reaction.
== History == Efficacy was evaluated in ARROS-1 (NCT05118789), a multi-center, single-arm, open-label, multi-cohort trial in participants with previously treated locally advanced or metastatic ROS1-positive NSCLC. The efficacy population included 117 participants; 59 who received one prior ROS1 tyrosine kinase inhibitor and 58 who received two or more prior ROS1 tyrosine kinase inhibitors, including lorlatinib, repotrectinib, and/or taletrectinib.
Signs and symptoms which (a) are suggestive of a connective tissue disease, but (b) do not meet the criteria of any defined connective tissue diseases, and (c) have lasted for at least three years. (Note, if less than three years, may be regarded as early UCTD). Positive ANA test on two different occasions.
=== Respiratory depression === Respiratory depression is the leading cause of death from opioid use. Although evidence is sparse, the risk of respiratory depression caused by taking kratom appears to be low, but, as of 2016, the Food and Drug Administration listed respiratory depression as a concern. A 2018 review found that the alkaloids in kratom do not induce respiratory depression.
Sources: en.wikipedia.org
Major artistic movements such as the abstract expressionism of Jackson Pollock and Willem de Kooning and the pop art of Andy Warhol and Roy Lichtenstein developed largely in the United States. Major photographers include Alfred Stieglitz, Edward Steichen, Dorothea Lange, Edward Weston, James Van Der Zee, Ansel Adams, and Gordon Parks. The tide of modernism and then postmodernism has brought global fame to American architects, including Frank Lloyd Wright, Philip Johnson, and Frank Gehry. The Metropolitan Museum of Art in Manhattan is the largest art museum in the United States and the fourth-largest in the world.
==== Clinical Laboratory Improvement Amendments (CLIA) ==== CMS ensures the integrity of laboratories performing testing via inspections and consistent oversight, bolstered with proficiency testing by accredited organizations. CLIA authorizes regulation of laboratories that conduct testing, not the individuals who order the tests or receive test results. All laboratories performing DTC testing must obtain CLIA certification and maintain compliance with national standards.
The reaction with a second amino acid allows for the ring to open, later forming an acylated unsaturated dipeptide. The reaction happens in a step-wise function which allows for the amino group to be protected and the azlactone to be produced. Catalytic hydrogenation and hydrolysis then take place in order to produce the dipeptide (4).
In the United States, opium poppies and poppy straw are prohibited. As the opium poppy is legal for culinary or aesthetic reasons, poppies were once grown as a cash crop by farmers in California. The law of poppy cultivation in the United States is somewhat ambiguous. The reason for the ambiguity is that the Opium Poppy Control Act of 1942 (now repealed) stated that any opium poppies should be declared illegal, except if the farmers were issued a state permit. § 3 of the Opium Poppy Control Act stated: It shall be unlawful for any person who is not the holder of a license authorizing him to produce the opium poppy, duly issued to him by the Secretary of the Treasury in accordance with the provisions of this Act, to produce the opium poppy, or to permit the production of the opium poppy in or upon any place owned, occupied, used, or controlled by him. This led to the Poppy Rebellion, and to the Narcotics Bureau arresting anyone planting opium poppies and forcing the destruction of poppy fields of anyone who defied the prohibition of poppy cultivation. Though the press of those days favoured the Federal Bureau of Narcotics, the state of California supported the farmers who grew opium poppies for their seeds for uses in foods such as poppy seed muffins. Today, this area of law has remained vague and remains somewhat controversial in the United States. The Opium Poppy Control Act of 1942 was repealed on 27 October 1970. Under the Federal Controlled Substances Act, opium poppy and poppy straw are listed as Schedule II drugs under ACSN 9630.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.